- Health insurance exchanges: HHS should enhance its management of open enrollment performance : report to Congressional requesters1
- Hospitals reported improved preparedness for emerging infectious diseases after the Ebola outbreak1
- How to prepare a pre-request for designation (pre-RFD)1
- Increases in reimbursement for brand-name drugs in Part D1
- Individuals' use of online medical records and technology for health needs1
- Labeling for biosimilar products1
- Liposome drug products: chemistry, manufacturing, and controls : human pharmacokinetics and bioavailability : and labeling documentation1
- Listing of ingredients in tobacco products: (revised)1
- Logical observation identifiers names and codes for in vitro diagnostic tests: guidance for industry and Food and Drug Administration staff1
- M7(R1) assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk1
- Medicaid Fraud Control Units fiscal year 2017 annual report1
- Medicaid eligibility, enrollment, and renewal processes and system study: case study summary report--New York1
- Medicaid eligibility, enrollment, and renewal processes and systems study: case study summary report--Arizona1
- Medicaid eligibility, enrollment, and renewal processes and systems study: case study summary report--Colorado1
- Medicaid eligibility, enrollment, and renewal processes and systems study: case study summary report--Florida1
- Medicaid eligibility, enrollment, and renewal processes and systems study: case study summary report--Idaho1
- Medicaid eligibility, enrollment, and renewal processes and systems study: case study summary report--North Carolina1
- Medical product communications that are consistent with the FDA-required labeling: questions and answers1
- Medicare Advantage appeal outcomes and audit findings raise concerns about service and payment denials1
- Medicare Part B drug payments: impact of price substitutions based on 2016 average sales prices1